Skip to main content
SpringerLink
Log in

The Glycogen Storage Diseases and Related Disorders

  • Chapter
Inborn Metabolic Diseases

Abstract

The liver glycogen storage disorders (GSDs) comprise GSD I, the hepatic presentations of GSD III, GSD IV, GSD VI, the liver forms of GSD IX, and GSD 0. GSD I, III, VI, and IX present similarly with hypoglycemia, marked hepatomegaly, and growth retardation. GSD I is the most severe affecting both glycogen breakdown and gluconeogenesis. In GSD Ib there is additionally a disorder of neutrophil function. Most patients with GSD III have a syndrome that includes hepatopathy, myopathy, and often cardiomyo pathy. GSD VI and GSD IX are the least severe: there is only a mild tendency to fasting hypoglycemia, liver size normalises with age, and patients reach normal adult height. GSD IV manifests in most patients in infancy or childhood as hepatic failure with cirrhosis leading to end-stage liver disease. GSD 0 presents in infancy or early childhood with fasting hypoglycemia and ketosis and, in contrast, with postprandial hyperglycemia and hyperlactatemia. Treatment is primarily dietary and aims to prevent hypoglycemia and suppress secondary metabolic decompensation. This usually requires frequent feeds by day, and in GSD I and in some patients with GSD III, continuous nocturnal gastric feeding.

The muscle glycogenoses fall into two clinical groups. The first comprises GSD V, GSD VII, the muscle forms of GSD IX (VIII according to McKusick), phosphoglycerate kinase deficiency (IX according to McKusick), GSD X, GSD XI, GSD XII and GSD XIII, and is characterised by exercise intolerance with exercise-induced myalgia and cramps, which are often followed by rhabdomyolysis and myoglobinuria; all symptoms are reversible with rest. Disorders in the second group, consisting of the myopathic form of GSD III, and rare neuromuscular forms of GSD IV, manifest as sub-acute or chronic myopathies, with weakness of trunk, limb, and respiratory muscles. Involvement of other organs (erythrocytes, central or peripheral nervous system, heart, liver) is possible, as most of these enzymes defects are not confined to skeletal muscle.

Generalized glycogenoses comprise GSD II, caused by the deficiency of a lysosomal enzyme, and Danon disease due to the deficiency of a lysosomal membrane protein. Recent work on myoclonus epilepsy with Lafora bodies (Lafora disease) suggests that this is a glycogenosis, probably due to abnormal glycogen synthesis. GSD II can be treated by enzyme replacement therapy, but there is no specific treatment for Danon and Lafora disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rake JP, Visser G, Labrune P et al (2002) Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161[Suppl 1]:S20–S34

    Article  PubMed  CAS  Google Scholar 

  2. Kuijpers TW, Maianski NA, Tool AT et al (2003) Apoptotic neutrophils in the circulation of patients with glycogen storage disease type 1b (GSD1b). Blood 101:5021–5024

    Article  PubMed  CAS  Google Scholar 

  3. Visser G, Rake JP, Fernandes J et al (2000) Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr 137:187–191

    Article  PubMed  CAS  Google Scholar 

  4. Foster JD, Nordlie RC (2002) The biochemistry and molecular biology of the glucose-6-phosphatase system. Exp Biol Med (May-wood) 227:601–608

    CAS  Google Scholar 

  5. Waddell ID, Burchell A (1993) Identification, purification and genetic deficiencies of the glucose-6-phosphatase system transport proteins. Eur J Pediatr 152[Suppl 1]: S14–S17

    Article  PubMed  CAS  Google Scholar 

  6. Veiga-da-Cunha M, Gerin I, Chen YT et al (1999) The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a. Eur J Hum Genet 7: 717–723

    Article  PubMed  CAS  Google Scholar 

  7. Burchell A (1998) A reevaluation of GLUT 7. Biochem J 331:973

    PubMed  CAS  Google Scholar 

  8. Melis D, Havelaar AC, Verbeek E et al (2004) NPT4, a new microsomal phosphate transporter: mutation analysis in glycogen storage disease type Ic. J Inherit Metab Dis 27: 725–733

    Article  PubMed  CAS  Google Scholar 

  9. Collins JE, Bartlett K, Leonard JV, Ayynsley-Green A (1990) Glucose production rates in type 1 glycogen storage disease. J Inherit Metab Dis 13:195–206

    Article  PubMed  CAS  Google Scholar 

  10. Fernandes J (1974) The effect of disaccharides on the hyperlactacidaemia of glucose-6-phosphatase-deficient children. Acta Paediatr Scand 63: 695–698

    PubMed  CAS  Google Scholar 

  11. Fernandes J, Alaupovic P, Wit JM (1989) Gastric drip feeding in patients with glycogen storage disease type I: its effects on growth and plasma lipids and apolipoproteins. Pediatr Res 25: 327–331

    PubMed  CAS  Google Scholar 

  12. Greene HL, Swift LL, Knapp HR (1991) Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease. J Pediatr 119:398–403

    Article  PubMed  CAS  Google Scholar 

  13. Alaupovic P, Fernandes J (1985) The serum apolipoprotein profile of patients with glucose-6-phosphatase deficiency. Pediatr Res 19:380–384

    PubMed  CAS  Google Scholar 

  14. Bandsma RH, Smit GP, Kuipers F (2002) Disturbed lipid metabolism in glycogen storage disease type 1. Eur J Pediatr 161[Suppl 1]:S65–S69

    Article  PubMed  CAS  Google Scholar 

  15. Fernandes J, Pikaar NA (1972) Ketosis in hepatic glycogenosis. Arch DisChild 47: 41–46

    CAS  Google Scholar 

  16. Greene HL, Wilson FA, Hefferan P et al (1978) ATP depletion, a possible role in the pathogenesis of hyperuricemia in glycogen storage disease type I. J Clin Invest 62:321–328

    PubMed  CAS  Google Scholar 

  17. Cohen JL, Vinik A, Faller J, Fox IH (1985) Hyperuricemia in glycogen storage disease type I. Contributions by hypoglycemia and hyperglucagonemia to increased urate production. J Clin Invest 75: 251–257

    PubMed  CAS  Google Scholar 

  18. Matern D, Seydewitz HH, Bali D, Lang C, Chen YT (2002) Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr 161[Suppl 1]: S10–S19

    Article  PubMed  CAS  Google Scholar 

  19. Rake JP, ten Berge AM, Visser G et al (2000) Glycogen storage disease type Ia: recent experience with mutation analysis, a summary of mutations reported in the literature and a newly developed diagnostic flow chart. Eur J Pediatr 159:322–330

    Article  PubMed  CAS  Google Scholar 

  20. Chou JY, Matern D, Mansfield BC, Chen YT (2002) Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med 2:121–143

    Article  PubMed  CAS  Google Scholar 

  21. Lin B, Hiraiwa H, Pan CJ, Nordlie RC, Chou JY (1999) Type-1c glycogen storage disease is not caused by mutations in the glucose-6-phosphate transporter gene. Hum Genet 105:515–517

    Article  PubMed  CAS  Google Scholar 

  22. Narisawa K, Otomo H, Igarashi Y et al (1983) Glycogen storage disease type 1b: microsomal glucose-6-phosphatase system in two patients with different clinical findings. Pediatr Res 17:545–549

    PubMed  CAS  Google Scholar 

  23. Burr IM, O’Neill JA, Karzon DT, Howard LJ, Greene HL (1974) Comparison of the effects of total parenteral nutrition, continuous intragastric feeding, and portacaval shunt on a patient with type I glycogen storage disease. J Pediatr 85:792–795

    Article  PubMed  CAS  Google Scholar 

  24. Chen YT, Cornblath M, Sidbury JB (1984) Cornstarch therapy in type I glycogen-storage disease. N Engl J Med 310:171–175

    Article  PubMed  CAS  Google Scholar 

  25. Wolfsdorf JI, Crigler JF, Jr (1999) Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease. J Pediatr Gastroenterol Nutr 29:136–143

    Article  PubMed  CAS  Google Scholar 

  26. Smit GP, Ververs MT, Belderok B, Van Rijn M, Berger R, Fernandes J (1988) Complex carbohydrates in the dietary management of patients with glycogenosis caused by glucose-6-phosphatase deficiency. Am J Clin Nutr 48:95–97

    PubMed  CAS  Google Scholar 

  27. Wolfsdorf JI, Keller RJ, Landy H, Crigler JF, Jr (1990) Glucose therapy for glycogenosis type 1 in infants: comparison of intermittent uncooked cornstarch and continuous overnight glucose feedings. J Pediatr 117:384–391

    Article  PubMed  CAS  Google Scholar 

  28. Fernandes J, Berger R, Smit GP (1984) Lactate as a cerebral metabolic fuel for glucose-6-phosphatase deficient children. Pediatr Res 18:335–339

    PubMed  CAS  Google Scholar 

  29. Daublin G, Schwahn B, Wendel U (2002) Type I glycogen storage disease: favourable outcome on a strict management regimen avoiding increased lactate production during childhood and adolescence. Eur J Pediatr 161[Suppl 1]:S40–S45

    Article  PubMed  CAS  Google Scholar 

  30. Weinstein DA., Somers MJ, Wolfsdorf JI (2001) Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr 138:378–382

    Article  PubMed  CAS  Google Scholar 

  31. Wittenstein B, Klein M, Finckh B, Ullrich K, Kohlschutter A (2002) Radical trapping in glycogen storage disease 1a. Eur J Pediatr 161[Suppl 1]:S70–S74

    Article  PubMed  CAS  Google Scholar 

  32. Bandsma RH, Rake JP, Visser G et al (2002) Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a. J Pediatr 140:256–260

    Article  PubMed  CAS  Google Scholar 

  33. Mairovitz V, Labrune P, Fernandez H, Audibert F, Frydman R (2002) Contraception and pregnancy in women affected by glycogen storage diseases. Eur J Pediatr 161[Suppl 1]:S97–101

    Article  PubMed  CAS  Google Scholar 

  34. Kerr KG (1999) The prophylaxis of bacterial infections in neutropenic patients. J Antimicrob Chemother 44:587–591

    Article  PubMed  CAS  Google Scholar 

  35. Visser G, Rake JP, Labrune P et al (2002) Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 161[Suppl 1]:S83–S87

    Article  PubMed  CAS  Google Scholar 

  36. Visser G, Rake JP, Labrune P et al (2002) Consensus guidelines for management of glycogen storage disease type 1b-European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 161[Suppl 1]:S120–S123

    Article  PubMed  Google Scholar 

  37. Simmons PS, Smithson WA, Gronert GA, Haymond MW (1984) Acute myelogenous leukemia and malignant hyperthermia in a patient with type 1b glycogen storage disease. J Pediatr 105: 428–431

    Article  PubMed  CAS  Google Scholar 

  38. Donadieu J, Barkaoui M, Bezard F, Bertrand Y, Pondarre C, Guiband P (2000) Renal carcinoma in a patient with glycogen storage disease Ib receiving long-term granulocyte colony-stimulating factor therapy. J Pediatr Hematol Oncol 22:188–189

    Article  PubMed  CAS  Google Scholar 

  39. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP (2002) Guidelines for management of glycogen storage disease type I-European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161[Suppl 1]:S112–S119

    PubMed  Google Scholar 

  40. Hagen T, Korson MS, Wolfsdorf JI (2000) Urinary lactate excretion to monitor the efficacy of treatment of type I glycogen storage disease. Mol Genet Metab 70:189–195

    Article  PubMed  CAS  Google Scholar 

  41. Lee PJ, Chatterton C, Leonard JV (1996) Urinary lactate excretion in type 1 glycogenosis—a marker of metabolic control or renal tubular dysfunction? J Inherit Metab Dis 19:201–204

    Article  PubMed  CAS  Google Scholar 

  42. Visser G, Rake JP, Kokke FT, Nikkels PG, Sauer PJ, Smit GP (2002) Intestinal function in glycogen storage disease type I. J Inherit Metab Dis 25:261–267

    Article  PubMed  CAS  Google Scholar 

  43. Talente GM, Coleman RA, Alter C et al (1994) Glycogen storage disease in adults. Ann Intern Med 120:218–226

    PubMed  CAS  Google Scholar 

  44. Chen YT (1991) Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment. Pediatr Nephrol 5:71–76

    Article  PubMed  CAS  Google Scholar 

  45. Lee PJ, Dalton RN, Shah V, Hindmarsh PC, Leonard JV (1995) Glomerular and tubular function in glycogen storage disease. Pediatr Nephrol 9:705–710

    Article  PubMed  CAS  Google Scholar 

  46. Chen YT, Scheinman JI, Park HK, Coleman RA, Roe CR (1990) Amelioration of proximal renal tubular dysfunction in type I glycogen storage disease with dietary therapy. N Engl J Med 323:590–593

    Article  PubMed  CAS  Google Scholar 

  47. Iida S, Matsuoka K, Inouse M, Tomiyasu K, Noda S (2003) Calcium nephrolithiasis and distal tubular acidosis in type 1 glycogen storage disease. Int J Urol 10:56–58

    Article  PubMed  Google Scholar 

  48. Restaino I, Kaplan BS, Stanley C, Baker L (1993) Nephrolithiasis, hypocitraturia, and a distal renal tubular acidification defect in type 1 glycogen storage disease. J Pediatr 122:392–396

    PubMed  CAS  Google Scholar 

  49. Baker L, Dahlem S, Goldfarb S et al (1989) Hyperfiltration and renal disease in glycogen storage disease, type I. Kidney Int 35:1345–1350

    PubMed  CAS  Google Scholar 

  50. Chen YT, Coleman RA, Scheinman JI, Kolbeck PC, Sidbury JB (1988) Renal disease in type I glycogen storage disease. N Engl J Med 318:7–11

    Article  PubMed  CAS  Google Scholar 

  51. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M (1997) Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 24:276–279

    Article  PubMed  CAS  Google Scholar 

  52. Lee PJ (2002) Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 161[Suppl 1]: S46–S49

    Article  PubMed  CAS  Google Scholar 

  53. Bianchi L (1993) Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 152[Suppl 1]:S63–S70

    Article  PubMed  Google Scholar 

  54. Labrune P (2002) Glycogen storage disease type I: indications for liver and/or kidney transplantation. Eur J Pediatr 161[Suppl 1]:S53–S55

    Article  PubMed  Google Scholar 

  55. Matern D, Starzl TE, Arnaout W et al (1999) Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 158[Suppl 2]:S43–S48

    Article  PubMed  Google Scholar 

  56. Lee PJ, Patel JS, Fewtrell M, Leonard JV, Bishop NJ (1995) Bone mineralisation in type 1 glycogen storage disease. Eur J Pediatr 154:483–487

    PubMed  CAS  Google Scholar 

  57. Rake JP, Visser G, Huismans D et al (2003) Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study. J Inherit.Metab Dis 26:371–384

    Article  PubMed  CAS  Google Scholar 

  58. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC (2002) Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100:3776–3781

    Article  PubMed  CAS  Google Scholar 

  59. Lee PJ, Patel A, Hindmarsh PC, Mowat AP, Leonard JV (1995) The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: its association with hyper insulinism. Clin Endocrinol (Oxf) 42:601–606

    CAS  Google Scholar 

  60. Lee PJ, Celermajer DS, Robinson J, McCarthy SN, Betteridge DJ, Leonard JV (1994) Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a. Atherosclerosis 110:95–100

    Article  PubMed  CAS  Google Scholar 

  61. Corby DG, Putnam CW, Greene HL (1974) Impaired platelet function in glucose-6-phosphatase deficiency. J Pediatr 85:71–76

    Article  PubMed  CAS  Google Scholar 

  62. Trioche P, Francoual J, Capel L, Odievre M, Lindenbaum A, Labrune P (2000) Apolipoprotein E polymorphism and serum concentrations in patients with glycogen storage disease type Ia. J Inherit Metab Dis 23:107–112

    Article  PubMed  CAS  Google Scholar 

  63. Humbert M, Labrune P, Simonneau G (2002) Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr 161[Suppl 1]: S93–S96

    Article  PubMed  CAS  Google Scholar 

  64. DiMauro S, Hartwig GB, Hays A et al (1979) Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol 5:422–436

    Article  PubMed  CAS  Google Scholar 

  65. DiMauro S, Hays AP, Tsujino S (2004) Nonlysosomal glycogenosis. In: Engel AG, Franzini-Amstrong C (eds) Myology: basic and clinical. McGraw-Hill, New York, pp 1535–1558

    Google Scholar 

  66. Wolfsdorf JI, Weinstein DA (2003) Glycogen storage diseases. Rev Endocrinol Metab Disord 4:95–102

    Article  CAS  Google Scholar 

  67. Lucchiari S, Fogh I, Prelle A et al (2002) Clinical and genetic variability in glycogen storage disease type IIIa: Seven novel AGL gene mutations in the Mediterranean area. Am J Med Genet 109:183–190

    Article  PubMed  CAS  Google Scholar 

  68. Lee P (1999) Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gyneacol 106:181–182

    CAS  Google Scholar 

  69. de Moor RA, Schweizer JJ, van Hoek B, Wasser M, Vink R, Maaswinkel-Mooy PD (2000) Hepatocellular carcinoma in glycogen storage disease type IV. Arch Dis Child 82:479–480

    Article  PubMed  Google Scholar 

  70. Moses SW, Parvari R (2002) The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies. Curr Mol Med 2:177–188

    Article  PubMed  CAS  Google Scholar 

  71. Selby R, Starzl TE, Yunis E et al (1993) Liver transplantation for type I and type IV glycogen storage disease. Eur J Pediatr 152[Suppl 1]: S71–S76

    Article  PubMed  Google Scholar 

  72. Lossos A, Meiner Z, Barash V et al (1998) Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol 44:867–872

    Article  PubMed  CAS  Google Scholar 

  73. Tay SK, Akman HO, Chung WK et al (2004) Fatal infantile neuromuscular presentation of glycogen storage disease type IV. Neuromuscul Disord 14: 253–260

    Article  PubMed  Google Scholar 

  74. Bao Y, Kishnani P, Wu JY, Chen HT (1996) Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. J Clin Invest 97:941–948

    Article  PubMed  CAS  Google Scholar 

  75. Hendrickx J, Willems PJ (1996) Genetic deficiencies of the glycogen phosphorylase system. Hum Genet 97:551–556

    PubMed  CAS  Google Scholar 

  76. Huijing F, Fernandes J (1969) X-chromosomal inheritance of liver glycogenosis with phosphorylase kinase deficiency. Am J Hum Genet 21:275–284

    PubMed  CAS  Google Scholar 

  77. Arad M, Maron BJ, Gorham JM et al (2005) Glycogen storage disease presenting as hypertrophic cardiomyopathy. N Engl J Med 352:362–372

    Article  PubMed  CAS  Google Scholar 

  78. Fernandes J, Koster JF, Grose WF, Sorgedrager N (1974) Hepatic phosphorylase deficiency. Its differentiation from other hepatic glycogenoses. Arch Dis Child 49:186–191

    PubMed  CAS  Google Scholar 

  79. Willems PJ, Gerver WJ, Berger R, Fernandes J (1990) The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients. Eur J Pediatr 149:268–271

    Article  PubMed  CAS  Google Scholar 

  80. Hendrickx J, Dams E, Coucke P, Lee P, Fernandes J, Willems PJ (1996) X-linked liver glycogenosis type II (XLG II) is caused by mutations in PHKA2, the gene encoding the liver alpha subunit of phosphorylase kinase. Hum Mol Genet 5:649–652

    Article  PubMed  CAS  Google Scholar 

  81. Hendrickx J, Lee P, Keating JP et al (1999) Complete genomic structure and mutational spectrum of PHKA2 in patients with x-linked liver glycogenosis type I and II. Am J Hum Genet 64:1541–1549

    Article  PubMed  CAS  Google Scholar 

  82. Bruno C, Manfredi G, Andreu AL et al (1998) A splice junction mutation in the alpha(M) gene of phosphorylase kinase in a patient with myopathy. Biochem Biophys Res Commun 249:648–651

    Article  PubMed  CAS  Google Scholar 

  83. Wehner M, Clemens PR, Engel AG, Kilimann MW (1994) Human muscle glycogenosis due to phosphorylase kinase deficiency associated with a nonsense mutation in the muscle isoform of the alpha subunit. Hum Mol Genet 3:1983–1987

    PubMed  CAS  Google Scholar 

  84. Burwinkel B, Hu B, Schroers A et al (2003) Muscle glycogenosis with low phosphorylase kinase activity: mutations in PHKA1, PHKG1 or six other candidate genes explain only a minority of cases. Eur J Hum Genet 11:516–526

    Article  PubMed  CAS  Google Scholar 

  85. Schippers HM, Smit GP, Rake JP, Visser G (2003) Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency (GSD IX). J Inherit Metab Dis 26:43–47

    Article  PubMed  CAS  Google Scholar 

  86. Aynsley-Green A, Williamson DH, Gitzelmann R (1977) Hepatic glycogen synthetase deficiency. Definition of syndrome from metabolic and enzyme studies on a 9-year-old girl. Arch Dis Child 52:573–579

    Article  PubMed  CAS  Google Scholar 

  87. Laberge AM, Mitchell GA, van de Werve G, Lambert M (2003) Longterm follow-up of a new case of liver glycogen synthase deficiency. Am J Med Genet A 120:19–22

    Article  PubMed  Google Scholar 

  88. Orho M, Bosshard NU, Buist NR et al (1998) Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. J Clin Invest 102:507–515

    PubMed  CAS  Google Scholar 

  89. Tonin P, Lewis PJ, Servidei S, DiMauro S (1990) Metabolic causes of myoglobinuria. Ann Neurol 27:181–185

    Article  PubMed  CAS  Google Scholar 

  90. Martin MA, Rubio JC, Wevers RA et al (2004) Molecular analysis of myophosphorylase deficiency in Dutch patients with McArdle’s disease. Ann Hum Genet 68:17–22

    Article  PubMed  CAS  Google Scholar 

  91. Bartram C, Edwards RH, Clague J, Beynon RJ (1993) McArdle’s disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet 2:1291–1293

    PubMed  CAS  Google Scholar 

  92. el Schahawi M, Tsujino S, Shanske S, DiMauro S (1996) Diagnosis of McArdle’s disease by molecular genetic analysis of blood. Neurology 47:579–580

    PubMed  Google Scholar 

  93. Tsujino S, Shanske S, Carroll JE, Sabina RL, DiMauro S (1994) Two mutations, one novel and one frequently observed, in Japanese patients with McArdle’s disease. Hum Mol Genet 3:1005–1006

    PubMed  CAS  Google Scholar 

  94. Martinuzzi A, Sartori E, Fanin M et al (2003) Phenotype modulators in myophosphorylase deficiency. Ann Neurol 53:497–502

    Article  PubMed  CAS  Google Scholar 

  95. Kazemi-Esfarjani P, Skomorowska E, Jensen TD, Haller RG, Vissing A (2002) A nonischemic forearm exercise test for McArdle disease. Ann Neurol 52:153–159

    Article  PubMed  Google Scholar 

  96. Vissin J, Haller RG (2003) A diagnostic cycle test for McArdle’s disease. Ann Neurol 54:539–542

    Article  Google Scholar 

  97. Haller RG (2000) Treatment of McArdle disease. Arch Neurol 57:923–924

    Article  PubMed  CAS  Google Scholar 

  98. Vissing J, Haller RG (2003) The effect of oral sucrose on exercise tolerance in patients with McArdle’s disease. N Engl J Med 349: 2503–2509

    Article  PubMed  CAS  Google Scholar 

  99. Haller RG, Vissing J (2004) No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 62:82–86

    PubMed  CAS  Google Scholar 

  100. Morimoto A, Ueda I, Hirashima Y et al (2003) A novel missense mutation (1060G → C) in the phosphoglycerate kinase gene in a Japanese boy with chronic haemolytic anaemia, developmental delay and rhabdomyolysis. Br J Haematol 122:1009–1013

    Article  PubMed  CAS  Google Scholar 

  101. Schroder JM, Dodel R, Weis J, Stefanidis I, Reichmann H (1996) Mitochondrial changes in muscle phosphoglycerate kinase deficiency. Clin Neuropathol 15:34–40

    PubMed  CAS  Google Scholar 

  102. Vissing J, Schmalbruch H, Haller RG, Clausen T (1999) Muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene. Ann Neurol 46: 274–277

    Article  PubMed  CAS  Google Scholar 

  103. Kreuder J, Borkhardt A, Repp R et al (1996) Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med 334:1100–1104

    Article  PubMed  CAS  Google Scholar 

  104. Comi GP, Fortunato F, Lucchiari S et al (2001) Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann Neurol 50:202–207

    Article  PubMed  CAS  Google Scholar 

  105. Kanno T, Maekawa M (1995) Lactate dehydrogenase M-subunit deficiencies: clinical features, metabolic background, and genetic heterogeneities. Muscle Nerve 3:S54–S60

    Article  PubMed  CAS  Google Scholar 

  106. Holme E, Kollberg G, Oldfors A et al (2005) Muscular glycogen storage disease 0 — A new disease entity in a child with hypertrophic cardiomyopathy and myopathy due to a homozygous stop mutation in the muscular glycogen synthase gene (GYS1). J Inherit Metab Dis 28[Suppl 1]:214

    Google Scholar 

  107. Van den Hout HM, Hop W, van Diggelen OP et al (2003) The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340

    Article  PubMed  Google Scholar 

  108. Makos MM, McComb RD, Hart MN, Bennett DR (1987) Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship. Ann Neurol 22:629–633

    Article  PubMed  CAS  Google Scholar 

  109. Hagemans ML, Janssens AC, Winkel LP et al (2004) Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 63:1688–1692

    PubMed  CAS  Google Scholar 

  110. Van den Hout JM, Kamphoven JH, Winkel LP et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448–e457

    Article  PubMed  Google Scholar 

  111. Winkel LP, Van den Hout JM, Kamphoven JH et al (2004) Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol 55:495–502

    Article  PubMed  CAS  Google Scholar 

  112. Danon MJ, Oh SJ, DiMauro S et al (1981) Lysosomal glycogen storage disease with normal acid maltase. Neurology 31:51–57

    PubMed  CAS  Google Scholar 

  113. Nishino I, Fu J, Tanji K et al (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406:906–910

    Article  PubMed  CAS  Google Scholar 

  114. Dworzak F, Casazza F, Mora M et al (1994) Lysosomal glycogen storage with normal acid maltase: a familial study with successful heart transplant. Neuromuscul Disord 4:243–247

    Article  PubMed  CAS  Google Scholar 

  115. Minassian BA, Ianzano L, Meloche M et al (2000) Mutation spectrum and predicted function of laforin in Lafora’s progressive myoclonus epilepsy. Neurology 55:341–346

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Beatrix Children’s Hospital Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands

    G. Peter A. Smit & Jan Peter Rake

  2. Department of Neurology, Columbia University College of Physicians & Surgeons, 630 West 168th Street, P & S 4-443, New York, NY, 10032, USA

    Hasan O. Akman & Salvatore DiMauro

Authors
  1. G. Peter A. Smit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Peter Rake
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hasan O. Akman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salvatore DiMauro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, University Hospital Groningen, Burgemeester Weertslaan 31, 8162 DP, Epe, The Netherlands

    John Fernandes

  2. Unité de Métabolisme, Département de Pédiatrie, Hôpital Necker Enfants Malades, 149 Rue de Sèvres, 75043, Paris Cedex 15, France

    Jean-Marie Saudubray

  3. Metabolic Research Group, Christian de Duve Institute of Cellular Pathology, University of Louvain Medical School, Avenue Hippocrate 75-39, 1200, Brussels, Belgium

    Georges van den Berghe

  4. Willink Biochemical Genetics Unit, Royal Manchester Children’s Hospital, Hospital Road, Pendlebury, Manchester, M27 4HA, UK

    John H. Walter

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Smit, G.P.A., Rake, J.P., Akman, H.O., DiMauro, S. (2006). The Glycogen Storage Diseases and Related Disorders. In: Fernandes, J., Saudubray, JM., van den Berghe, G., Walter, J.H. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg . https://doi.org/10.1007/978-3-540-28785-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28785-8_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28783-4

  • Online ISBN: 978-3-540-28785-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation